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Background: Increased resistance by Plasmodium falciparum parasites led to the withdrawal of the antimalarial
drugs chloroquine and sulphadoxine-pyrimethamine in Ethiopia. Since 2004 artemether-lumefantrine has served to treat
uncomplicated P. falciparum malaria. However, increasing reports on delayed parasite clearance to artemisinin opens
up a new challenge in anti-malarial therapy. With the complete withdrawal of CQ for the treatment of Plasmodium
falciparum malaria, this study assessed the evolution of CQ resistance by investigating the prevalence of mutant
alleles in the pfmdr1 and pfcrt genes in P. falciparum and pvmdr1 gene in Plasmodium vivax in Southern and
Eastern Ethiopia.
Methods: Of the 1,416 febrile patients attending primary health facilities in Southern Ethiopia, 329 febrile
patients positive for P. falciparum or P. vivax were recruited. Similarly of the 1,304 febrile patients from Eastern
Ethiopia, 81 febrile patients positive for P. falciparum or P. vivax were included in the study. Of the 410 finger
prick blood samples collected from malaria patients, we used direct sequencing to investigate the prevalence
of mutations in pfcrt and pfmdr1. This included determining the gene copy number in pfmdr1 in 195 P. falciparum
clinical isolates, and mutations in the pvmdr1 locus in 215 P. vivax clinical isolates.
Results: The pfcrt K76 CQ-sensitive allele was observed in 84.1% of the investigated P.falciparum clinical isolates. The
pfcrt double mutations (K76T and C72S) were observed less than 3%. The pfcrt SVMNT haplotype was also found to
be present in clinical isolates from Ethiopia. The pfcrt CVMNK-sensitive haplotypes were frequently observed (95.9%).
The pfmdr1 mutation N86Y was observed only in 14.9% compared to 85.1% of the clinical isolates that carried sensitive
alleles. Also, the sensitive pfmdr1 Y184 allele was more common, in 94.9% of clinical isolates. None of the investigated
P. falciparum clinical isolates carried S1034C, N1042D and D1246Y pfmdr1 polymorphisms. All investigated P. falciparum
clinical isolates from Southern and Eastern Ethiopia carried only a single copy of the mutant pfmdr1 gene.
Conclusion: The study reports for the first time the return of chloroquine sensitive P. falciparum in Ethiopia. These
findings support the rationale for the use of CQ-based combination drugs as a possible future alternative.
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Malaria remains one of the major health problems in
sub-Saharan Africa [1,2]. Though there are encouraging
reports that malaria morbidity and mortality are declin-
ing [3], it is still an overwhelming public health problem,
with an estimated 207 million cases and 627,000 deaths
every year worldwide. Of all malaria deaths, 90% occur
in sub-Saharan Africa, and 77% in children under five
years of age [4]. One of the main obstacles to malaria
control is the ability of the parasites to develop resist-
ance to the administered anti-malarial drugs. Chloro-
quine (CQ) was the first antimalarial to be widely used
in endemic areas, but CQ resistance was documented in
Thailand in the late 1950’s, spread to African in 1974
[5], and subsequently came to East Africa in the early
1980’s [6]. Since 2009, there are increasing concerns
and reports of delayed parasite clearance to administered
artemisinin, especially in parts of Southeast Asia [7].
In Ethiopia, CQ treatment failure for Plasmodium
falciparum and Plasmodium vivax was documented in
1996 [8]. Therefore, in 1998 sulphadoxine-pyrimethamine
(SP) replaced the CQ triple-dose (25 mg base/kg) regimen
as the first-line drug for the treatment of uncomplicated
P. falciparum and mixed infection of P. falciparum and P.
vivax malaria. However, in a short time span P. falcip-
arum also developed resistance to SP, leading to thera-
peutic failure of SP [9-12]. Artemether-lumefantrine (AL)
(Coartem®) replaced SP in 2004 as a first-line drug to treat
uncomplicated P. falciparum and mixed infection of P.
falciparum and P.vivax malaria in Ethiopia [13]. However
CQ still remains the first-line drug to treat P. vivax mal-
aria in Ethiopia and sub-Saharan Africa. Although signifi-
cant progress has been made to understand the resistance
mechanisms to administered anti-malarial drugs, the gen-
etic basis of drug resistance is vital to implement strategies
for efficient malaria control.
Point mutations in the genes “P. falciparum multi-
drug resistance 1” (pfmdr1), located in chromosome 5
[14-17], “P. falciparum chloroquine resistance trans-
porter” (pfcrt), on chromosome 7 [18-20], and “P. vivax
multi-drug resistance 1” (pvmdr1) on chromosome 10
[21-23] are the most investigated genes for anti-malarial
drug resistance. Pfmdr1 encodes a trans-membrane
transporter, and point mutations in this gene modulate
the level of CQ resistance [24,25]. Other mutations are
also associated with anti-malarial drug resistance and
delayed parasite clearance [15,17,26,27]: in the codons
86 (Asn86Tyr), 184 (Tyr184Phe), 1034 (Ser1034Cys),
1042 (Asn1042Asp), 1246 (Asp1246Tyr) in pfmdr1; co-
dons 72 (Cys72Ser), 74 (Met74Ile), 75 (Asn75Glu) and
76 (Lys76Thr) in pfcrt; and codons 976 (Tyr976Phe)
and 1076 (Phe1076Leu) in pvmdr1. Additionally, several
other studies have also reported that pfcrt haplotypes are
associated with anti-malarial drug resistance [19,25,28].Gene copy number variations (CNV) in the P. falciparum
genome have been shown to influence parasite pheno-
types, and increased gene copy numbers are associated
with reduced susceptibility to anti-malarial drugs.
Mutations in the pfmdr1 locus are associated with anti-
malarial resistance to chloroquine, mefloquine, quinine or
artemisinin derivatives, whereas pfcrt mutations are asso-
ciated with chloroquine, amodiaquine, mefloquine and
artemisinin combination therapy [18]. Increased pfmdr1
gene copy numbers are associated with reduced suscepti-
bility of P. falciparum to anti-malarial drugs, especially
with artemether-lumefantrine and artesunate-mefloquine
[29]. In many countries that are prone to malaria en-
demics, P. vivax malaria is treated with CQ, as the drug
is well tolerated, affordable, has a longer half-life, and pro-
tects from early relapses [30-32]. A decline in CQ efficacy
for P. vivax malaria was reported in Papua New Guinea in
1989 [33] and in northwestern Sumatra, Indonesia in 1995
[34]. CQ resistance in P. vivax in Ethiopia was reported in
2008, when four patients out of 83(4.8%) had recurrent
parasitaemia on Day 28 [35].
Several studies at regular intervals are required to evalu-
ate drug resistance based on the genetic diversity of circu-
lating P. falciparum strains and their molecular markers
for P. falciparum resistance to CQ and AL. Such studies
will lay a basis to re-evaluate existing strategies in malaria
control [36]. In the present study, the prevalence of mu-
tations in pfcrt and pfmdr1, the gene copy number of
pfmdr1 in P. falciparum, and point mutations in pvmdr1
in P. vivax were investigated in clinical isolates from
Southern and Eastern Ethiopia.
Methods
Study sites
A health institution-based study targeting febrile patients
attending primary health facilities was conducted in
Southern and Eastern Ethiopia. Samples from Southern
Ethiopia were collected between the months of August
and December, 2011, at three health centres: Omo Nada,
Bala Wajo, and Arba Minch. In Eastern Ethiopia samples
were collected in the Harar health centre between the
months of October and December 2009. Malaria trans-
mission in these study sites is seasonal, with higher trans-
mission following the rainy seasons (between September
and December, and between April and May).
Study samples
Study participants were recruited from the routine
health delivery system. Self-presenting febrile patients
attending health centers in Omo Nada (n = 713), Bala
Wajo (n = 312), and Arba Minch (n = 391), and whose
age was at least six months between August and December
2011, were eligible for the current study. Additionally self-
presenting febrile patients attending Harar health centre
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study. An axillary temperature was measured to check for
a fever. Patients with an axillary temperature of ≥37°C
were considered febrile. Any patient reported as being
infected either with P. falciparum or P. vivax or with a
mixed infection using the existing health care delivery sys-
tem within the target health centres were approached for
consent immediately after receiving their laboratory result.
For those who consented to be part of the study, approxi-
mately 5–10 μL of a finger-prick blood sample was col-
lected. No additional clinical assessment was carried out
at the time of recruitment. A total of 410 Southern and
Eastern Ethiopian finger-prick blood samples collected on
Whatman 3 mm filter paper tested positive by microscopy
for either P. falciparum or vivax. Of these, 195 tested posi-
tive for P. falciparum (170 from Southern Ethiopia and 25
from Eastern Ethiopia), and 215 for P. vivax (159 P. vivax
from Southern Ethiopia and 56 from Eastern Ethiopia).
The blood spots were air-dried and stored in a separate,
clean, sealed plastic bag at room temperature for further
molecular analysis.
Blood film management
After fixing the thin film in methanol, both smears were
stained with 3% Giemsa for 30 min and examined under
oil immersion for malaria parasites. Thick films were
used for parasite detection, and thin film for species
identification. At least 100 fields examined under an
oil-immersion lens were examined before ruling out
infection.Table 1 Primer pairs used to amplify and sequence pfcrt, pfm
Gene fragment Primer Name Primer sequen
Pfcrt SNPs at OF P1 5′CCGTTAATAA
Codon 72&76 OR P2 5′CGGATGTTAC
NF P3 5′-AGGTTCTTGT
NR P4 5′-CAAAACTATA
Pfmdr1 SNPs at OF P5 5′-AGGTTGAAA
Codon 86&184 OR P6 5′-ATGACACCA
NF P7 5′-ACAAAAAGA
NR P8 5′-AAACGCAAG
Pfmdr1 SNPs at OF P9 5′-GTGTATTTGC
Codon 1034 OR P10 5′-GACATATTAA
1042 and 1246 NF P11 5′ CAGATGATG
NR 12 5′-TAAATAACAT
pvmdr1at codon OF P13 5′-GCGAACTCG
976 and 1076 OF P14 5′GGCGTAGCTT
NF P15 5′-GGATTGCTGT
NF P16 5′AGAGGGATTT
OF: Outer Forward; OR: Outer Nested; P1-P12: Primers; NF: Nested Forward; NR: Nes
1; pfcrt: Plasmodium falciparum chloroquine resistance transporter; pvmdr1: PlasmodDetection of pfmdr1, pfcrt and pvmdr1 polymorphisms
DNA was isolated using the Qiagen DNA Mini Kit for
blood and tissue (QIAGEN, Germany), following the
manufacturer’s instructions, and it was then stored at
−20°C until use. Nested PCR was carried out as previ-
ously described elsewhere [37]. DNA samples were amp-
lified by species-specific primer pairs (Table 1). For pfcrt,
pfmdr1 and pvmdr1 both the primary and nested ampli-
fications were carried out in a 20 μL reaction volume
containing 1X buffer, 2.5 mM MgCl2, 200 μM dNTPs,
200nM primers, 1U Taq DNA-Polymerase, and 10 ng of
DNA template on a PTC-200 Thermal cycler (MJ Re-
search, USA). Each genus-specific amplification for Plas-
modium was followed by a species-specific PCR. For
amplifications, the study followed standard nested PCR
procedure (Table 1). The PCR product of the first reac-
tion was used as the template for the second in all
nested PCRs. Amplicons that resulted from the nested
PCRs were separated by electrophoresis on a 1.2% agar-
ose gel, run with a 100 bp DNA ladder (Invitrogen,
Karlsruhe, Germany). The presence of different Plasmo-
dium species was re-confirmed by checking amplicon
size. To identify relevant Single Nucleotide Polymor-
phisms (SNPs) in pfmdr1, pfcrt and pvmdr1, PCR prod-
ucts were cleaned using Exo-SAP-IT (USB, Affymetrix,
USA), and 1 μL of the purified product was used as a
template for direct sequencing using the Big Dye termin-
ator v. 2.0 cycle sequencing kit (Applied Biosystems,
USA) on an ABI 3130XL DNA sequencer, according to
the manufacturer’s instructions [38]. All investigateddr1 and pvmdr1
ce PCR cycling conditions
TAAATACACGCG 35 cycles of 94°C for 30 s; 56°C
AAAACTATAGTCC for 30 s; and 62°C for 1 min;
CTTGGTAAATTTGC 30 cycles of 94°C for 30 s; 56°C
GTTACCAATTTTG for 30 s; and 65°C for 1 min;
AAGAGTTGAAC 30 cycles of 94°C for 30 s; 55°C
CAAACATAAAT for 30 s; and 65°C for 1 min;
GTACCGCTGAAT 30 cycles of 94°C 30 s; 60°C
TAATACATAAAGTC for 30 s; and 65°C for 1 min;
TGTAAGAGCT 34 cycles of 94°C for 30 s; 55°C
ATAACATGGGTTC for 1 min and 72°C for 1.5
AAATGTTTAAAGATC 29 cycles of 94°C for 30 s; 60°C
GGGTTCTTGACT for 30 s; and 65°C for 1 min;
AATAAGTACTCCCTCTA 45 cycles of 94°C for 5 min,
CCCGTAAATAAA 530C for 1 min and 720C for 1 min
CAGCACATATTAACA 45 cycles of 94°C for 5 min,
CATAAAGTCATT 650C for 1 min and 720C for 1 min
ted Reverse; bp: base pair; pfmdr1: Plasmodium falciparum multi-drug resistance
ium. vivax multi-drug resistance 1.
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trated in Table 2.
Detection of pfmdr1 gene copy number variations
The pfmdr1 gene copy number was estimated by TaqMan
real-time PCR, as previously described [29]. Briefly, 10 ng
of genomic DNA was amplified in a 25 μL volume of reac-
tion mixture containing 1x TaqMan buffer (8% glycerol,
0.625 U DNA polymerase, 5.5 mmol/L MgCl2, 300 μmol/
L dNTPs, 600 nmol/L passive reference dye ROX (5-
carboxy-X-rhodamine), pH 8.3), 300 nmol/L of each
forward and reverse primer, 100 nmol/L of each
probe, and 5 μL of template DNA on a Corbett Re-
search RG-3000 (Qiagen, Hilden, Germany). Thermal
cycling parameters were as follows: pre-incubation at
95°C for 5 minutes, followed by 50 cycles of 15 sec-
onds at 95°C and 1 minute at 58°C. Genomic DNA
from P. falciparum reference 3D7, reported to have
only one copy, was used as the calibrator [39], and P.
falciparum ß-tubulin as the house-keeping gene. For
multiple pfmdr1 copy number control, DNA from the
Dd2 clone was used. The 2-ΔΔCt method of relative quanti-
fication [40] was used to estimate copy number. Using this
cycle threshold (Ct) method to estimate copy numbers of
unknown samples, a calibrator DNA template with known
copies of the interest and a house-keeping gene which has
the same copy number was utilized. The ΔΔCt calculation
was as follows: ΔΔCt = (Ct target gene - Ct Pf ß-tubulin)
X - (Ct target gene - Ct Pf ß-tubulin) Y, where X = un-
known sample and Y = P. falciparum 3D7. The result was
expressed in N-fold changes in X target gene copies nor-
malized to P. falciparum ß-tubulin according to the equa-
tion (amount of target) = 2-ΔΔCt. Each sample was run as
triplicate, and the mean and standard deviation of the
three Ct values were calculated and computed for specifi-
city as suggested earlier [29].
Ethics
Ethical approvals were obtained from the review boards
of Aklilu Lemma Institute of Pathobiology (ALIPB), Col-
lege of Health Sciences of Jimma University, College of
Health and Medical Sciences of Haramaya University
and Armauer Hansen Research Institute (AHRI). After
obtaining informed consent and assent from either the
patient or legal guardian, blood samples were collected
from individuals positive for P. falciparum or P. vivax.Table 2 Investigated point mutations in pfmdr1, pfcrt and pvm
Pfmdr1 locus
Codon position 86 184 1034 1042 1246
Wild type/Mutant TGA/TGT ATA/ATT CAG/CTG TTA/TTG GAG/GA
ns substitution Asn/Tyr Tyr/Phe Ser/Cys Asn/Asp Asp/Tyr
ns: non synonymous ; pfmdr1: Plasmodium falciparum multi-drug resistance 1; pfcrt:
vivax multi-drug resistance 1.The study participation was voluntary and had no influ-
ence on the treatment provision at the respective health
facilities. All patient information was kept confidential.
All individuals positive for P. falciparum were treated
with AL, while P. vivax positive patients were treated
with CQ.
Results
The observed frequencies of the investigated SNPs in
the pfmdr1, pfcrt and the pvmdr1 loci are summarized
in Table 3. The pfcrt K76T (Lys76Thr) mutation was ob-
served in only 15.9% (31/195) of the clinical isolates in-
vestigated compared to 84.1% (164/195) wild type allele
that were sensitive to CQ. The pfcrt C72S (Cys72Ser)
was observed only in 3.6% (7/195) compared to 96.4%
(188/195) wild type allele that were sensitive to CQ. The
pfcrt double mutations (K76T and C72S) were observed
in less than 2.6% of individuals (5/195) Table 3. For the
investigated pfmdr1 locus N86Y(Asn86Tyr), the muta-
tion was observed in 14.9% (29/195) of the clinical iso-
lates compared to 85.1% (166/195) wild type that carried
sensitive alleles. The investigated pfmdr1 locus Y184
(Tyr184Phe), only 5.1% (10/195) of the clinical isolates
carried the mutant. None of the investigated 195 P.
falciparum clinical isolates carried S1034C, N1042D and
D1246Y of pfmdr1 polymorphisms. For the investigated
pvmdr1 locus Y976 (Tyr976Phe), the mutation was
observed in 32.6% (70/215) of the clinical isolates com-
pared to 67.7% (145/215) wild type that carried sensitive
alleles, whereas the investigated F1076 (Phe1076Leu)
carried no drug resistant mutants Table 3. Of the all
investigated P. falciparum clinical isolates from Southern
and Eastern Ethiopia, only one copy of pfmdr1 gene
copy number was observed.
The frequency of SNPs in the pfmdr1, pfcrt and the
pvmdr1 loci in Southern and Eastern Ethiopia are summa-
rized in Table 4. The pfcrt K76T mutation in Southern
Ethiopia was 13.5% (23/170) of the clinical isolates inves-
tigated compared to 86.5% (147/170) wild type allele that
were sensitive to CQ. The pfmdr1 locus N86Y was ob-
served in 12.9% (22/170) compared to 87.1% (148/170)
wild type allele that were sensitive to CQ. In Eastern
Ethiopia, SNPs in the pfmdr1 locus N86Y and pfcrt locus
K76T were 28.0% (7/25) and 32.0% (8/25) respectively. On
the other hand, for the investigated pvmdr1 locus Y976
(Tyr976Phe), the mutation was observed in 37.1% (59/dr1genes
Pfcrt locus Pvmdr1 locus
72 74 75 76 976 1076
T TGT/AGT ATG/ATT AAT/GAA AAA/ACA TAC/TTC TTT/CTT
Cys/Ser Met/Ile Asn/Glu Lys/Thr Tyr/Phe Phe/Leu
Plasmodium falciparum chloroquine resistance transporter; pvmdr1: Plasmodium
Table 3 Distribution of pfcrt, pfmdr1 and pvmdr1 point
mutations in the investigated clinical isolates
P. falciparum number %
no resistance alleles detected 127 65%
Pfcrt only C72 7 3.6%
C72 and K76 5 2.6%
only K76 31 15.9%
pfcrt and pfmdr1 K76 and N86 4 2.1%
pfmdr1 only N86 29 14.9%
N86 and Y184 8 4.1%
only Y184 10 5.1%
Total 195
P. vivax
no resistance alleles detected 145 74%
pvmdr1 only Y976 70 32.6%
only F1076 0 0%
Total 145
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to 19.6% (11/56) in Eastern Ethiopia.
The pfcrt haplotypes were reconstructed for mutations
at codons 72–76 in all P. falciparum isolates. The pfcrt
wild type Cysteine-Valine-Methionine-Asparagine-Lysine
(pfcrt CVMNK) mutates to either Cysteine-Valine-
Isoleucine-Glutamate-Threonine (pfcrt CVIET) or
Serine-Valine-Methionine-Asparagine-Threonine (pfcrt
SVMNT) variants Table 5. The mutated pfcrt SVMNT
haplotype was observed in 4.1% (8/195) of the iso-
lates, whereas pfcrt CVMNK of wildtype was observed
in 95.9% (187/195) Table 5. No pfcrt CVIET haplo-
types were observed.Table 4 Distribution of pfcrt, pfmdr1 and pvmdr1 point
mutations in the investigated clinical isolates in Southern
and Eastern Ethiopia
P. falciparum SE no SE (%) EE no EE (%)
Pfcrt only C72 5 2.9% 2 8.0%
C72 and K76 4 2.4% 1 4.0%
only K76 23 13.5% 8 32.0%
pfcrt and pfmdr1 K76 and N86 2 1.2% 2 8.0%
pfmdr1 only N86 22 12.9% 7 28.0%
N86 and Y184 6 3.5% 2 8.0%
only Y184 7 4.1% 3 12.0%
P. vivax
pvmdr1 only Y976 59 37.1% 11 19.6%
only F1076 0 0.0%
pfmdr1: Plasmodium falciparum multi-drug resistance 1; pfcrt: Plasmodium
falciparum chloroquine resistance transporter; pvmdr1: Plasmodium. vivax
multi-drug resistance 1; SE: Southern Ethiopia; EE: Eastern Ethiopia.Discussion
The aim of the current study was to investigate the
prevalence of mutant SNPs in the loci pfmdr1, pfcrt, and
pvmdr1, as well as copy number variations in pfmdr1, all
of which are associated with anti-malarial drug resist-
ance. A large proportion of P. falciparum clinical isolates
in this study (84.1%) carried the chloroquine-susceptible
pfcrt K76 allele. Previously it has been reported that the
CQ-resistant mutation pfcrt K76T is a strong predictor
of overall CQ resistance, and thus it is used as a bio-
marker of CQ resistance [16]. It appears that CQ-
susceptible Plasmodium falciparum isolates are back in
circulation in Ethiopia.
The finding of this study does not support a previous
study conducted in Ethiopia that reported a 100% fre-
quency of the pfcrt T76 mutation, and an 81% frequency
of the mutation pfmdr1 Y86 in P. falciparum [41]. How-
ever, the current finding is in line with studies con-
ducted in two East African countries [27,42], where the
frequency of the pfcrt-76 resistance alleles were repopu-
lated with the sensitive ones after many years of CQ
withdrawal. Studies showed that pfcrt mutations at co-
dons 72 to 76 with non-synonymous substitutions result
in wildtype pfcrt CVMNK or other pfcrt haplotypes
CVIET or SVMNT that have been associated with CQ
resistance[43]. The wild type pfcrt CVMNK haplotypes
were observed in 187 (95.9%) of the P. falciparum iso-
lates. The mutant pfcrt SVMNT was carried by 4.1% (8/
195) of the investigated isolates, and it was identical to
that of chloroquine resistant isolates identified in South-
East Asia [44]. These are the first findings on the pres-
ence of the pfcrt SVMNT haplotype in clinical isolates
in Ethiopia. This is an interesting finding and novel to
the study as the SVMNT haplotype is still very rare in
Africa. So far few studies reported the presence of this
haplotype in African countries [45-48], of this haplotype
mostly associated with amodiaquine resistance and lower
level of chloroquine resistance compared to CVIET
[49,50]. The pfcrt CVIET haplotypes were not detected
here, although it is prevalent in Africa [51].
Concerning pfmdr1, while wild-type pfmdr1 is thought
to transport and accumulate CQ in the parasites’ food
vacuole, mutations N86Y, S1034C, N1042D, and D1246Y
interfere with transportation of the anti-malarial drugs,
leading to reduced CQ-sensitivity [14]. The percentage of
wild-type alleles at codon 86 of pfmdr1 was 85.1% (166/
195), which is higher than 81% present in Schunk in 2006
and 84.5% in Eshetu in 2010 [41,52]. It should be clear
that the study by Schunk in 2006 was conducted
7 years before the current study. This is clear that
as the time difference between these two studies is
large and with reduced drug pressure on CQ over
time might have contributed to the return of CQ
susceptibility.
Table 5 Distribution of reconstructed Pfcrt haplotypes from clinical isolates from South and Eastern Ethiopia
Locus haplotype Investigated fragment (5′-3′) Number (%)
pfcrt 74-76 CVMNK (Sensitive) 5′-TAATTGAAACAATTTTTG-3′ 187 (95.9)
SVMNT (Mutant) 5′-TAATGAATAAAATTTTTG-3′ 8 (4.1)
CVIET (Mutant) 5′-TAATGAATACAATTTTTG-3′ 0
pfmdr1: Plasmodium falciparum multi-drug resistance 1; pfcrt: Plasmodium falciparum chloroquine resistance transporter; pvmdr1: Plasmodium vivax multi-drug
resistance 1.
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13.5% (23/170) of the clinical isolates investigated com-
pared to 86.5% (147/170) wild type allele that were sen-
sitive to CQ. The pfmdr1 locus N86Y was observed in
12.9% (22/170) compared to 87.1% (148/170) wild type
allele that were sensitive to CQ. In Eastern Ethiopia,
SNPs in the pfmdr1 locus N86Y and pfcrt locus K76T
were 28.0% (7/25) and 32% (8/25) respectively. There
was no statistical difference between Southern and
Eastern Ethiopia in SNPs in the pfmdr1 locus N86Y and
pfcrt locus K76T (P = 0.9).
Double mutations in pvmdr1 at positions Y976F and
F1076L have been suggested to be associated with re-
duced chloroquine susceptibility to P. vivax in Thailand
and Indonesia, the two countries where P. vivax is
prevalent. Other studies have addressed whether chloro-
quine or amodiaquine treatment failure might be associ-
ated with P. vivax isolates carrying the Y976F substitution
[53]. Pvmdr1 sequences from P.vivax, the orthologue of
pfmdr1, were analyzed for the presence of mutations at
positions 976 and 1076, and we found that 32.6%
(70/215) of the isolates carried the F976 SNP. Muta-
tions were not detected at codon 1076 in all P. vivax
isolates studied here. On the other hand, for the in-
vestigated pvmdr1 locus Y976 (Tyr976Phe), the muta-
tion was observed in 37.1% (59/159) of the clinical
isolates from Southern Ethiopia compared to 19.6%
(11/56) from Eastern Ethiopia.
In line with the current study, studies conducted in
Madagascar and Brazil showed that F1076L cannot be
taken as an indicator of drug resistance, but rather it is a
geographic variant [46,53,54]. Earlier, in vivo studies
conducted in Ethiopia confirmed the presence of drug
resistant P. vivax [8,35]. However, these studies were
confounded by the inherent difficulties associated with
in vivo tests for relapsing malaria [55] and the difficulties
in differentiating between re-infection, recrudescence,
and relapse after treatment failure [56].
A high proportion (97.9%, 191/195) of samples had
chloroquine (CQ)-susceptible alleles at both codon 76
of pfcrt and codon 86 of pfmdr1. The rapid shift in P.
falciparum from CQ-resistant to CQ-susceptible sug-
gests that the removal of CQ for the treatment of P.
falciparum or the pressure from AL that has been used
since 2004 to treat falciparum malaria and mixed infec-
tion of P.falciparum and P. vivax or both may eventuallylead to replacement of pfmdr1 resistance genes by
susceptible parasite populations [42,57]. Our finding was
consistent with observations from Malawi [57], Kenya
[42], and Tanzania [27], where the withdrawal of chloro-
quine resulted in the rapid spread of a chloroquine-
susceptible Pfcrt K76 population. In Malawi, recovery
of the susceptible Pfcrt-K76 from <15% to 100% within
13 years of CQ withdrawal has been reported [57]. More-
over, a study confirmed that the pfmdr1 alleles 86 N, 184 F,
and 1246D significantly increased in prevalence after AL
treatment [58]. In another in vivo study, P. falciparum par-
asites carrying the chloroquine-susceptible pfcrt K76 allele
was selected after treatment with AL [59].
It was difficult to determine whether the CQ-
susceptible resurgence is due to back-mutations in the
CQ-resistant allele or the expansion of surviving CQ-
susceptible reservoir populations. Re-expansion appears
to be more common in Africa, where transmission rates
are higher and naturally immune individuals are more
common than in Southeast Asia (where CQ-resistant al-
leles appear to have gone to fixation in many areas) [57].
It does not appear that CQ-resistant mutants in Ethiopia
acquired mutations to compensate for the costs of being
drug-resistant. It is believed that such compensatory
mutations confer fitness levels greater than that of the
original CQ-susceptible and CQ-resistant alleles [60].
CQ-susceptible alleles clearly have a selective advantage
over resistant ones, pfmdr1 Y86 having rebounded from
100% to 11% in 6 years (for samples collected on 2009
from East Ethiopia) to eight years time (for samples col-
lected on 2011from South Ethiopia). On the other hand,
N86Y mutation was rebounded from 81% to 9% [41,52].
In Ethiopia, due to resistance developed by P. falciparum,
replacement of SP by artemether-lumefantrine has been
mandatory. Since 2004, artemether-lumefantrine has been
the drug of choice for the treatment of P. falciparum
malaria. Unlike Malawi, in Ethiopia CQ was partially with-
drawn and is still the drug of choice for the treatment of
uncomplicated P. vivax. This finding shows that there has
been strong selection for chloroquine-sensitive parasites
after the nationwide replacement of chloroquine with SP.
The return of chloroquine-susceptible alleles in a country
like Ethiopia, which is endemic for malaria, can be consid-
ered a positive development toward replacing the expensive
artemether-lumefantrine with a safe and cheap form of CQ
in combination with other short-acting drugs. Likewise, in
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quine sensitivity have a positive impact on public health
[57].Conclusion
The return of CQ-sensitive parasites is likely due to
either CQ withdrawal for the treatment of P. falciparum
or the pressure from AL since 2004 or both. The return
of CQ-susceptible P. falciparum following declining CQ
resistance will have its own contribution in the battle
against malaria. If chloroquine susceptibility does be-
come widespread in Ethiopia,the possibility of using
chloroquine in the future as a combination therapy with
other short-acting drugs with different pharmacokinetic
and pharmacodynamics profiles will be an additional
anti-malarial option. This is a positive development,
since CQ is cheap, safe, well-tolerated, long-lasting,
and easy-to-prepare molecule. Additional surveillance
studies to investigate resistance markers of pfmdr1
and Pfcrt genes of P. falciparum in the same geo-
graphic area may help to assess the prevalence of anti-
malarial resistance.
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